首页 > 最新文献

Anales Del Sistema Sanitario De Navarra最新文献

英文 中文
[Excess of mortality and mortality from COVID-19 and other causes of death in 2020 in Navarra, Spain]. [2020年西班牙纳瓦拉市因COVID-19和其他原因造成的超额死亡率和死亡率]。
IF 1 4区 医学 Q3 Medicine Pub Date : 2022-12-05 DOI: 10.23938/ASSN.1018
Conchi Moreno-Iribas, Yugo Floristán, Irene Iniesta Martinez, Eva Ardanaz Aicua, Marcela Guevara Eslava, Josu Delfrade

Background: In this study, we aimed to present mortality indicators from a database of death causes by age and sex in Navarre (Spain) for 2020: life expectancy at birth, excess mortality, and mortality from COVID-19 and other causes.

Methods: A Poisson regression model, which accounts for temporal trends in the previous years, was used to estimate the expected deaths by sex and age for 2020.

Results: Life expectancy at birth in Navarre for 2020 was 80.6 and 85.9 years for men and women, respectively, 1.4 and 1.0 years lower than in 2019. Deaths in people aged <55 years were similar to those expected. The highest adjusted excess mortality rate occurred among men and women aged >85 years, were 61% of excess deaths was concentrated. The estimated number of excess deaths did not exceed the number of reported deaths from COVID-19. In individuals aged >75 years, around 9 out of 10 people died from COVID-19. Coinciding with the COVID-19 pandemic, there was a remarkable decrease in mortality in people affected by diseases where dementia is included.

Conclusions: The first and second waves of the COVID-19 pandemic reduced life expectancy at birth to figures observed ten years ago. The increase in deaths in Navarre for 2020 is largely attributable to COVID-19.

背景:在本研究中,我们旨在从西班牙纳瓦拉(Navarre)按年龄和性别分列的死因数据库中获取2020年的死亡率指标:出生时预期寿命、超额死亡率、COVID-19和其他原因导致的死亡率。方法:采用泊松回归模型,根据前几年的时间趋势,估计2020年按性别和年龄划分的预期死亡人数。结果:2020年纳瓦拉地区男性和女性出生时预期寿命分别为80.6岁和85.9岁,比2019年分别降低1.4岁和1.0岁。85岁以上人群的死亡集中在61%的超额死亡中。估计的超额死亡人数没有超过COVID-19报告的死亡人数。在75岁以上的人群中,约有90%的人死于COVID-19。在2019冠状病毒病大流行期间,包括痴呆症在内的疾病患者的死亡率显著下降。结论:第一波和第二波COVID-19大流行使出生时预期寿命降至10年前的水平。2020年纳瓦拉死亡人数的增加主要归因于COVID-19。
{"title":"[Excess of mortality and mortality from COVID-19 and other causes of death in 2020 in Navarra, Spain].","authors":"Conchi Moreno-Iribas,&nbsp;Yugo Floristán,&nbsp;Irene Iniesta Martinez,&nbsp;Eva Ardanaz Aicua,&nbsp;Marcela Guevara Eslava,&nbsp;Josu Delfrade","doi":"10.23938/ASSN.1018","DOIUrl":"https://doi.org/10.23938/ASSN.1018","url":null,"abstract":"<p><strong>Background: </strong>In this study, we aimed to present mortality indicators from a database of death causes by age and sex in Navarre (Spain) for 2020: life expectancy at birth, excess mortality, and mortality from COVID-19 and other causes.</p><p><strong>Methods: </strong>A Poisson regression model, which accounts for temporal trends in the previous years, was used to estimate the expected deaths by sex and age for 2020.</p><p><strong>Results: </strong>Life expectancy at birth in Navarre for 2020 was 80.6 and 85.9 years for men and women, respectively, 1.4 and 1.0 years lower than in 2019. Deaths in people aged <55 years were similar to those expected. The highest adjusted excess mortality rate occurred among men and women aged >85 years, were 61% of excess deaths was concentrated. The estimated number of excess deaths did not exceed the number of reported deaths from COVID-19. In individuals aged >75 years, around 9 out of 10 people died from COVID-19. Coinciding with the COVID-19 pandemic, there was a remarkable decrease in mortality in people affected by diseases where dementia is included.</p><p><strong>Conclusions: </strong>The first and second waves of the COVID-19 pandemic reduced life expectancy at birth to figures observed ten years ago. The increase in deaths in Navarre for 2020 is largely attributable to COVID-19.</p>","PeriodicalId":7775,"journal":{"name":"Anales Del Sistema Sanitario De Navarra","volume":"45 3","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/cb/assn-45-03-e1018.PMC10065036.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9294498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Capillaroscopy, microangiopathy, and HIV. Descriptive study of capillaroscopy findings in HIV positive patients]. [毛细血管镜检查,微血管病变和HIV。]HIV阳性患者毛细管镜检查结果的描述性研究[j]。
IF 1 4区 医学 Q3 Medicine Pub Date : 2022-12-05 DOI: 10.23938/ASSN.1015
Guillermo Verdejo-Muñoz, César Gálvez-Barrón, Borja Gracia Tello, Sara Gamarra Calvo, Isabel Sanjoaquín Conde, Andrés Catena, José Ramón Blanco Ramos

Background: In this study, we aim to evaluate microangiopathy in HIV positive patients by using capillaroscopy. To date, few studies have been published on the topic. Capillaroscopy may be a tool for early diagnosis of cardiovascular involvement in this patient population.

Methodology: Cross-sectional study with HIV positive patients >18 years. The enrolment period was set from January to June 2018. The following data were collected: demographic (sex, age), laboratory tests (duration of infection, CD4 cell count, CD4:CD8 ratio, coinfection with other viruses), antiretroviral treatment, dyslipidemia, and comorbidities (active smoking, alcoholism, high blood pressure, dyslipidaemia, diabetes, cardiopathy). The capillaroscopy and blood tests were performed simultaneously. The following alterations were evaluated in the capillaroscopy: congestion, tortuosity, haemorrhage, dilations, capillary loss, and presence of megacapillaries.

Results: One hundred and two patients were included; 73.5% were male, mean age was 40 years (SD: 10), and mean duration of infection 4.5 years (SD: 3.1). At diagnosis, mean CD4 cell count was 408/mm3 and CD4/CD8 ratio 0.4. A number of patients (14.7%) were coinfected with the hepatitis B virus; 31.3% were active smokers and 13.7% alcoholics. Capillaroscopy alterations were found in most study patients (93.1%): congestion (78.5%), tortuosity (77.5%), haemorrhage (13.8%), dilations (11.8%), capillary loss (5%), and megacapillaries (1%). Capillary tortuosity was associated with age and smoking; and haemorrhage with age, CD4, antiretroviral treatment, and hypertension.

Conclusion: Prevalence of capillaroscopy alterations is high in HIV positive patients, particularly tortuosity and congestion. To the best of our knowledge, the later alteration has not been previously reported in this group of patients.

背景:在本研究中,我们旨在通过毛细管镜检查来评估HIV阳性患者的微血管病变。迄今为止,关于这一主题的研究很少发表。毛细管镜检查可能是早期诊断心血管疾病的一种工具。方法:对18岁以上的HIV阳性患者进行横断面研究。招生时间为2018年1月至6月。收集了以下数据:人口统计学(性别、年龄)、实验室检查(感染持续时间、CD4细胞计数、CD4:CD8比值、合并感染其他病毒)、抗逆转录病毒治疗、血脂异常和合并症(吸烟、酗酒、高血压、血脂异常、糖尿病、心脏病)。毛细血管镜检查和血液检查同时进行。在毛细血管镜检查中评估以下改变:充血、扭曲、出血、扩张、毛细血管丢失和巨毛细血管的存在。结果:纳入102例患者;73.5%为男性,平均年龄40岁(SD: 10),平均感染时间4.5年(SD: 3.1)。诊断时平均CD4细胞计数408/mm3, CD4/CD8比值0.4。一些患者(14.7%)合并感染乙型肝炎病毒;31.3%为活跃吸烟者,13.7%为酗酒者。大多数研究患者(93.1%)发现毛细血管镜改变:充血(78.5%)、扭曲(77.5%)、出血(13.8%)、扩张(11.8%)、毛细血管丢失(5%)和巨毛细血管(1%)。毛细血管扭曲与年龄和吸烟有关;出血与年龄、CD4、抗逆转录病毒治疗和高血压有关。结论:HIV阳性患者的毛细血管镜检查改变发生率高,尤其是扭曲和充血。据我们所知,在这组患者中,后来的改变以前没有报道过。
{"title":"[Capillaroscopy, microangiopathy, and HIV. Descriptive study of capillaroscopy findings in HIV positive patients].","authors":"Guillermo Verdejo-Muñoz,&nbsp;César Gálvez-Barrón,&nbsp;Borja Gracia Tello,&nbsp;Sara Gamarra Calvo,&nbsp;Isabel Sanjoaquín Conde,&nbsp;Andrés Catena,&nbsp;José Ramón Blanco Ramos","doi":"10.23938/ASSN.1015","DOIUrl":"https://doi.org/10.23938/ASSN.1015","url":null,"abstract":"<p><strong>Background: </strong>In this study, we aim to evaluate microangiopathy in HIV positive patients by using capillaroscopy. To date, few studies have been published on the topic. Capillaroscopy may be a tool for early diagnosis of cardiovascular involvement in this patient population.</p><p><strong>Methodology: </strong>Cross-sectional study with HIV positive patients >18 years. The enrolment period was set from January to June 2018. The following data were collected: demographic (sex, age), laboratory tests (duration of infection, CD4 cell count, CD4:CD8 ratio, coinfection with other viruses), antiretroviral treatment, dyslipidemia, and comorbidities (active smoking, alcoholism, high blood pressure, dyslipidaemia, diabetes, cardiopathy). The capillaroscopy and blood tests were performed simultaneously. The following alterations were evaluated in the capillaroscopy: congestion, tortuosity, haemorrhage, dilations, capillary loss, and presence of megacapillaries.</p><p><strong>Results: </strong>One hundred and two patients were included; 73.5% were male, mean age was 40 years (SD: 10), and mean duration of infection 4.5 years (SD: 3.1). At diagnosis, mean CD4 cell count was 408/mm3 and CD4/CD8 ratio 0.4. A number of patients (14.7%) were coinfected with the hepatitis B virus; 31.3% were active smokers and 13.7% alcoholics. Capillaroscopy alterations were found in most study patients (93.1%): congestion (78.5%), tortuosity (77.5%), haemorrhage (13.8%), dilations (11.8%), capillary loss (5%), and megacapillaries (1%). Capillary tortuosity was associated with age and smoking; and haemorrhage with age, CD4, antiretroviral treatment, and hypertension.</p><p><strong>Conclusion: </strong>Prevalence of capillaroscopy alterations is high in HIV positive patients, particularly tortuosity and congestion. To the best of our knowledge, the later alteration has not been previously reported in this group of patients.</p>","PeriodicalId":7775,"journal":{"name":"Anales Del Sistema Sanitario De Navarra","volume":"45 3","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/4f/assn-45-03-e1015.PMC10065037.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9351530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Assessment of pain in patients with rheumatic disease under biological therapy treatment]. [风湿病患者在生物治疗下的疼痛评估]。
IF 1 4区 医学 Q3 Medicine Pub Date : 2022-11-22 DOI: 10.23938/ASSN.1020
María Pilar Monforte Gasque, Esteban Manuel Lázaro Gallardo, Ana María Lázaro Castellano, Ana Cristina Querol Hernández, Estrella Maroto García, Ferrán Borrás Martí

Background: To assess pain in patients with rheumatic disease under biological therapy treatment.

Methods: Observational retrospective study of patients with rheumatic disease under biological therapy treatment who visited the health care center as outpatients in February/August 2020. We collected demographic (sex and age), clinical (diagnosis, pain presence, intensity, and location), and pharmacological (biological therapy, concomitant treatment with traditional DMARDs, and analgesic treatment) variables from the electronic medical records and Farmatools Dominion®.

Results: We included 138 patients; mean age was 56 years and 71% were female. The most frequent diagnosis (47%) was ankylosing spondylitis. Anti-TNF-a was the most prescribed biological drug (64%); 60.1% of study patients received traditional drugs, particularly methotrexate and leflunomide (51.8 and 28.9%, respectively). Pain was reported in 81% of the cases, particularly in hands (73.2%) and knees (69.6%); mean pain intensity was 6.5 (VAS). Although 83.3% of the patients had been prescribed analgesics, pain persisted in 84.8% of the cases (VAS >4), being severe or very severe in 67.9%. Over half of the patients (52.2%) used more than one analgesic. The most frequently prescribed medications were non-steroidal anti-inflammatory drugs (NSAIDs) (60%), paracetamol (52.2%), and opioids (56.5%). NSAIDs controlled pain (14.5%) better than opioids (8.3%); there was no post-treatment improvement of pain in 29.6% of the patients. The number of prescribed drugs increased with pain intensity (rho= 0.264; p= 0.006).

Conclusion: Almost 70% of study patients had uncontrolled severe rheumatic-related pain. This implies a challenge for esta­blishing effective treatments for this type of pain.

背景:评估风湿病患者在生物治疗下的疼痛。方法:对2020年2月/ 8月到卫生保健中心门诊接受生物治疗的风湿病患者进行观察性回顾性研究。我们从电子病历和Farmatools Dominion®收集了人口统计学(性别和年龄)、临床(诊断、疼痛存在、强度和位置)和药理学(生物治疗、传统DMARDs的伴随治疗和镇痛治疗)变量。结果:我们纳入了138例患者;平均年龄56岁,71%为女性。最常见的诊断是强直性脊柱炎(47%)。抗tnf -a是处方最多的生物药物(64%);60.1%的研究患者接受传统药物治疗,特别是甲氨蝶呤和来氟米特(分别为51.8%和28.9%)。81%的病例报告疼痛,特别是手部(73.2%)和膝盖(69.6%);平均疼痛强度为6.5 (VAS)。尽管83.3%的患者已经开了镇痛药,但84.8%的患者持续疼痛(VAS >4), 67.9%的患者为重度或极重度。超过一半的患者(52.2%)使用一种以上的镇痛药。最常见的处方药是非甾体类抗炎药(NSAIDs)(60%)、扑热息痛(52.2%)和阿片类药物(56.5%)。非甾体抗炎药对疼痛的控制(14.5%)优于阿片类药物(8.3%);29.6%的患者治疗后疼痛无改善。处方药物数量随疼痛强度的增加而增加(rho= 0.264;p = 0.006)。结论:几乎70%的研究患者有无法控制的严重风湿病相关疼痛。这意味着为这种类型的疼痛建立有效的治疗方法是一个挑战。
{"title":"[Assessment of pain in patients with rheumatic disease under biological therapy treatment].","authors":"María Pilar Monforte Gasque,&nbsp;Esteban Manuel Lázaro Gallardo,&nbsp;Ana María Lázaro Castellano,&nbsp;Ana Cristina Querol Hernández,&nbsp;Estrella Maroto García,&nbsp;Ferrán Borrás Martí","doi":"10.23938/ASSN.1020","DOIUrl":"https://doi.org/10.23938/ASSN.1020","url":null,"abstract":"<p><strong>Background: </strong>To assess pain in patients with rheumatic disease under biological therapy treatment.</p><p><strong>Methods: </strong>Observational retrospective study of patients with rheumatic disease under biological therapy treatment who visited the health care center as outpatients in February/August 2020. We collected demographic (sex and age), clinical (diagnosis, pain presence, intensity, and location), and pharmacological (biological therapy, concomitant treatment with traditional DMARDs, and analgesic treatment) variables from the electronic medical records and Farmatools Dominion®.</p><p><strong>Results: </strong>We included 138 patients; mean age was 56 years and 71% were female. The most frequent diagnosis (47%) was ankylosing spondylitis. Anti-TNF-a was the most prescribed biological drug (64%); 60.1% of study patients received traditional drugs, particularly methotrexate and leflunomide (51.8 and 28.9%, respectively). Pain was reported in 81% of the cases, particularly in hands (73.2%) and knees (69.6%); mean pain intensity was 6.5 (VAS). Although 83.3% of the patients had been prescribed analgesics, pain persisted in 84.8% of the cases (VAS >4), being severe or very severe in 67.9%. Over half of the patients (52.2%) used more than one analgesic. The most frequently prescribed medications were non-steroidal anti-inflammatory drugs (NSAIDs) (60%), paracetamol (52.2%), and opioids (56.5%). NSAIDs controlled pain (14.5%) better than opioids (8.3%); there was no post-treatment improvement of pain in 29.6% of the patients. The number of prescribed drugs increased with pain intensity (rho= 0.264; p= 0.006).</p><p><strong>Conclusion: </strong>Almost 70% of study patients had uncontrolled severe rheumatic-related pain. This implies a challenge for esta­blishing effective treatments for this type of pain.</p>","PeriodicalId":7775,"journal":{"name":"Anales Del Sistema Sanitario De Navarra","volume":"45 3","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/8f/assn-45-03-e1020.PMC10065035.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9298542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Irreversible electroporation: present and future in the treatment of hepatocellular carcinoma]. 不可逆电穿孔:肝细胞癌治疗的现状与未来。
IF 1 4区 医学 Q3 Medicine Pub Date : 2022-11-21 DOI: 10.23938/ASSN.1019
David Cano, Juan José Lasarte, Isabel Vivas

Currently, among the possible treatments for hepatocellular carcinoma there is group of minimally invasive ablation techniques with wide clinical acceptance due to their greater efficacy and safety in comparison to traditional therapies, low cost, and no need of being admitted to hospital (outpatient treatment program). Irreversible electroporation is a non-thermal ablation technique in which electrical fields are used to create nanopores in the cell membrane that induce tumor cell death. Irreversible electroporation has shown promising results in numerous clinical trials; however, its control on long-term tumor growth and recurrence is inferior in comparison to that of radiofrequency. Combining irreversible electroporation with immunological agents may increase its efficacy in the treatment of focal lesions and metastases. In this work, we present an update on IRE including procedure, mechanism of action, application as a treatment for HCC, and the improvements that have been made in the past few years.

目前,在肝细胞癌可能的治疗方法中,有一组微创消融技术因其比传统治疗方法更有效、更安全、成本低、无需住院(门诊治疗方案)而被临床广泛接受。不可逆电穿孔是一种非热消融技术,利用电场在细胞膜上形成纳米孔,诱导肿瘤细胞死亡。不可逆电穿孔在许多临床试验中显示出有希望的结果;然而,与射频相比,它对肿瘤长期生长和复发的控制较差。不可逆电穿孔联合免疫制剂可提高其治疗局灶性病变和转移性肿瘤的疗效。在这项工作中,我们介绍了IRE的最新进展,包括程序、作用机制、作为HCC治疗的应用以及在过去几年中所取得的进步。
{"title":"[Irreversible electroporation: present and future in the treatment of hepatocellular carcinoma].","authors":"David Cano,&nbsp;Juan José Lasarte,&nbsp;Isabel Vivas","doi":"10.23938/ASSN.1019","DOIUrl":"https://doi.org/10.23938/ASSN.1019","url":null,"abstract":"<p><p>Currently, among the possible treatments for hepatocellular carcinoma there is group of minimally invasive ablation techniques with wide clinical acceptance due to their greater efficacy and safety in comparison to traditional therapies, low cost, and no need of being admitted to hospital (outpatient treatment program). Irreversible electroporation is a non-thermal ablation technique in which electrical fields are used to create nanopores in the cell membrane that induce tumor cell death. Irreversible electroporation has shown promising results in numerous clinical trials; however, its control on long-term tumor growth and recurrence is inferior in comparison to that of radiofrequency. Combining irreversible electroporation with immunological agents may increase its efficacy in the treatment of focal lesions and metastases. In this work, we present an update on IRE including procedure, mechanism of action, application as a treatment for HCC, and the improvements that have been made in the past few years.</p>","PeriodicalId":7775,"journal":{"name":"Anales Del Sistema Sanitario De Navarra","volume":"45 3","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/72/assn-45-03-e1019.PMC10065056.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9303504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A clinical case of occupational cutaneous tuberculosis in the healthcare field]. 【卫生保健领域职业性皮肤结核临床一例】。
IF 1 4区 医学 Q3 Medicine Pub Date : 2022-11-21 DOI: 10.23938/ASSN.1022
Asan Mollov, Laura Otano-Oroz, Belén Asenjo-Redin, Montserrat Ojer-Zapata

Cutaneous tuberculosis is a rare extrapulmonary pre-sentation of tuberculosis, caused by mycobacterial species of the Mycobacterium tuberculosis complex. We describe a case of cutaneous tuberculosis in a 57-year-old technician from the microbiology laboratory in our hospital. She accidentally experienced a needlestick injury with a hollow needle while at work. Skin lesion developed shortly after on the punctured finger. A biopsy was performed, revealing necrotizing (caseating) granulomatous inflammation. Pharmacological treatment was initiated with four standard drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol hydrochloride. Improvement was observed, but the initial treatment had to be suspended due to intolerance to some of the drugs and changed to a treatment with isoniazid, rifampicin, and levofloxacin. The long duration of the treatment may increase the risk of toxic effects, making it necessary to discard the drug causing these effects and change the treatment regimen.

皮肤结核是一种罕见的肺外结核的先兆,由结核分枝杆菌复合体的分枝杆菌种类引起。我们报告一个57岁的皮肤结核病例,来自我们医院微生物实验室的技术人员。她在工作时不小心被空心针刺伤了。被刺破的手指上很快出现了皮肤损伤。活检显示坏死性肉芽肿性炎症。药物治疗开始使用四种标准药物:异烟肼、利福平、吡嗪酰胺和盐酸乙胺丁醇。观察到改善,但由于对某些药物不耐受,最初的治疗不得不暂停,改为异烟肼、利福平和左氧氟沙星治疗。长时间的治疗可能会增加毒性作用的风险,因此有必要放弃引起这些作用的药物并改变治疗方案。
{"title":"[A clinical case of occupational cutaneous tuberculosis in the healthcare field].","authors":"Asan Mollov,&nbsp;Laura Otano-Oroz,&nbsp;Belén Asenjo-Redin,&nbsp;Montserrat Ojer-Zapata","doi":"10.23938/ASSN.1022","DOIUrl":"https://doi.org/10.23938/ASSN.1022","url":null,"abstract":"<p><p>Cutaneous tuberculosis is a rare extrapulmonary pre-sentation of tuberculosis, caused by mycobacterial species of the Mycobacterium tuberculosis complex. We describe a case of cutaneous tuberculosis in a 57-year-old technician from the microbiology laboratory in our hospital. She accidentally experienced a needlestick injury with a hollow needle while at work. Skin lesion developed shortly after on the punctured finger. A biopsy was performed, revealing necrotizing (caseating) granulomatous inflammation. Pharmacological treatment was initiated with four standard drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol hydrochloride. Improvement was observed, but the initial treatment had to be suspended due to intolerance to some of the drugs and changed to a treatment with isoniazid, rifampicin, and levofloxacin. The long duration of the treatment may increase the risk of toxic effects, making it necessary to discard the drug causing these effects and change the treatment regimen.</p>","PeriodicalId":7775,"journal":{"name":"Anales Del Sistema Sanitario De Navarra","volume":"45 3","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/21/assn-45-03-e1022.PMC10065030.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9303503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Pediatric genital lichen sclerosus: a case series of 11 girls]. [小儿生殖器硬化性地衣:11例女孩]。
IF 1 4区 医学 Q3 Medicine Pub Date : 2022-11-18 DOI: 10.23938/ASSN.1014
Jorge Aróstegui Aguilar, Leire Loidi, Ingrid Hiltun, Mónica Larrea, Lourdes Cascante, Juan Ignacio Yanguas

Background: Genital lichen sclerosus decreases the quality of life of women; 10-15% of cases occur in prepubertal girls.

Methods: Retrospective and descriptive study on the characteristics of girls diagnosed with genital lichen sclerosus at the Hospital Universitario de Navarra (Pamplona, Spain) between 2019 and 2022.

Results: Eleven girls aged between 4 and 14 year-old were diagnosed. Frequently, diagnostic delays were up to two years after the appearance of the lesions; the girl with a four-year delay showed a significant vulvar architectural alteration. All cases showed the typical sclerotic lesions on the genital area, and two of them also on the back. While six patients were asymptomatic, the rest reported pruritus and/or pain. Treatment with high/very high potency topical cortico-steroids achieved a good partial response, without complete remission of the lesions.

Conclusion: Early diagnosis of genital lichen sclerosus is key to start early treatment, avoiding ireversible genital structural alteration.

背景:生殖器硬化地衣降低女性的生活质量;10-15%的病例发生在青春期前的女孩。方法:回顾性和描述性研究2019年至2022年在西班牙潘普洛纳纳瓦拉大学医院诊断为生殖器硬化性地衣的女孩的特征。结果:11名年龄在4 ~ 14岁的女孩被确诊。通常,诊断延误长达两年的病变出现后;延迟4年的女孩外阴结构明显改变。所有病例均表现为生殖器区典型的硬化性病变,其中2例也出现在背部。6例患者无症状,其余报告瘙痒和/或疼痛。高/非常高效力的局部皮质类固醇治疗取得了良好的部分反应,没有完全缓解病变。结论:早期诊断是早期治疗的关键,避免不可逆转的生殖器结构改变。
{"title":"[Pediatric genital lichen sclerosus: a case series of 11 girls].","authors":"Jorge Aróstegui Aguilar,&nbsp;Leire Loidi,&nbsp;Ingrid Hiltun,&nbsp;Mónica Larrea,&nbsp;Lourdes Cascante,&nbsp;Juan Ignacio Yanguas","doi":"10.23938/ASSN.1014","DOIUrl":"https://doi.org/10.23938/ASSN.1014","url":null,"abstract":"<p><strong>Background: </strong>Genital lichen sclerosus decreases the quality of life of women; 10-15% of cases occur in prepubertal girls.</p><p><strong>Methods: </strong>Retrospective and descriptive study on the characteristics of girls diagnosed with genital lichen sclerosus at the Hospital Universitario de Navarra (Pamplona, Spain) between 2019 and 2022.</p><p><strong>Results: </strong>Eleven girls aged between 4 and 14 year-old were diagnosed. Frequently, diagnostic delays were up to two years after the appearance of the lesions; the girl with a four-year delay showed a significant vulvar architectural alteration. All cases showed the typical sclerotic lesions on the genital area, and two of them also on the back. While six patients were asymptomatic, the rest reported pruritus and/or pain. Treatment with high/very high potency topical cortico-steroids achieved a good partial response, without complete remission of the lesions.</p><p><strong>Conclusion: </strong>Early diagnosis of genital lichen sclerosus is key to start early treatment, avoiding ireversible genital structural alteration.</p>","PeriodicalId":7775,"journal":{"name":"Anales Del Sistema Sanitario De Navarra","volume":"45 3","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/d3/assn-45-03-e1014.PMC10065031.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9652611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Systematic review on the effectiveness of cognitive multisensory rehabilitation]. 认知多感觉康复效果的系统综述
IF 1 4区 医学 Q3 Medicine Pub Date : 2022-11-18 DOI: 10.23938/ASSN.1013
María Del Cuvillo Yges, Adrián Arranz Escudero, Paloma Moreta de Esteban, José Javier López-Marcos, Patricia Martín-Casas

Cognitive multisensory rehabilitation (CMR) -a therapeutic approach to help recover movement using neurocognitive exercises- activates patient's perceptive and cognitive processes, key for motor learning. The aim of this systematic review was to assess the effectiveness of CMR on motor function and quality of life and compare the findings with other rehabilitation approaches or no-intervention in neurological and trauma adult and pediatric patients. We carried out a systematic review of randomized controlled clinical trials, pilot studies, and case series in PubMed, PEDro, Cochrane Library, and the CINHAL Complete database published between 2012 and 2021. Ten studies met the eligibility criteria. CMR provides similar or superior benefits compared to other types of approaches for the restoration of upper limb function, gait, balance, and quality of life in neurological and trauma patients. Further research with larger samples and higher methodological quality need to be developed to de-termine its long-term effectiveness.

认知多感觉康复(CMR)是一种通过神经认知练习来帮助恢复运动的治疗方法,它激活了患者的感知和认知过程,这是运动学习的关键。本系统综述的目的是评估CMR对运动功能和生活质量的有效性,并将其与其他康复方法或无干预的神经和创伤成人和儿童患者的研究结果进行比较。我们对2012年至2021年间发表的PubMed、PEDro、Cochrane Library和CINHAL Complete数据库中的随机对照临床试验、试点研究和病例系列进行了系统综述。10项研究符合入选标准。与其他类型的入路相比,CMR在恢复神经和创伤患者的上肢功能、步态、平衡和生活质量方面提供了类似或更好的益处。需要开展更大样本和更高方法学质量的进一步研究,以确定其长期有效性。
{"title":"[Systematic review on the effectiveness of cognitive multisensory rehabilitation].","authors":"María Del Cuvillo Yges,&nbsp;Adrián Arranz Escudero,&nbsp;Paloma Moreta de Esteban,&nbsp;José Javier López-Marcos,&nbsp;Patricia Martín-Casas","doi":"10.23938/ASSN.1013","DOIUrl":"https://doi.org/10.23938/ASSN.1013","url":null,"abstract":"<p><p>Cognitive multisensory rehabilitation (CMR) -a therapeutic approach to help recover movement using neurocognitive exercises- activates patient's perceptive and cognitive processes, key for motor learning. The aim of this systematic review was to assess the effectiveness of CMR on motor function and quality of life and compare the findings with other rehabilitation approaches or no-intervention in neurological and trauma adult and pediatric patients. We carried out a systematic review of randomized controlled clinical trials, pilot studies, and case series in PubMed, PEDro, Cochrane Library, and the CINHAL Complete database published between 2012 and 2021. Ten studies met the eligibility criteria. CMR provides similar or superior benefits compared to other types of approaches for the restoration of upper limb function, gait, balance, and quality of life in neurological and trauma patients. Further research with larger samples and higher methodological quality need to be developed to de-termine its long-term effectiveness.</p>","PeriodicalId":7775,"journal":{"name":"Anales Del Sistema Sanitario De Navarra","volume":"45 3","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/db/86/assn-45-03-e1013.PMC10065038.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9652609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Treatment of non-malignant chronic pain: paradigm shift and multidisciplinary management]. 非恶性慢性疼痛的治疗:范式转变和多学科管理。
IF 1 4区 医学 Q3 Medicine Pub Date : 2022-08-30 DOI: 10.23938/ASSN.1010
N Varela
{"title":"[Treatment of non-malignant chronic pain: paradigm shift and multidisciplinary management].","authors":"N Varela","doi":"10.23938/ASSN.1010","DOIUrl":"https://doi.org/10.23938/ASSN.1010","url":null,"abstract":"","PeriodicalId":7775,"journal":{"name":"Anales Del Sistema Sanitario De Navarra","volume":"45 2","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/fb/assn-45-02-e1010.PMC10130789.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9353558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Non-drug treatments for chronic non-malignant pain]. 【慢性非恶性疼痛的非药物治疗】。
IF 1 4区 医学 Q3 Medicine Pub Date : 2022-08-30 DOI: 10.23938/ASSN.1011
M V Ruiz-Romero, M D Guerra-Martín, L Álvarez-Tellado, E Sánchez-Villar, A Arroyo-Rodríguez, M C Sánchez-Gutiérrez
{"title":"[Non-drug treatments for chronic non-malignant pain].","authors":"M V Ruiz-Romero,&nbsp;M D Guerra-Martín,&nbsp;L Álvarez-Tellado,&nbsp;E Sánchez-Villar,&nbsp;A Arroyo-Rodríguez,&nbsp;M C Sánchez-Gutiérrez","doi":"10.23938/ASSN.1011","DOIUrl":"https://doi.org/10.23938/ASSN.1011","url":null,"abstract":"","PeriodicalId":7775,"journal":{"name":"Anales Del Sistema Sanitario De Navarra","volume":"45 2","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/42/af/assn-45-02-e1011.PMC10130788.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9353557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[25 years sharing knowledge]. [25年的知识分享]。
IF 1 4区 医学 Q3 Medicine Pub Date : 2022-08-30 DOI: 10.23938/ASSN.1012
O Díaz de Rada, C Beorlegui
{"title":"[25 years sharing knowledge].","authors":"O Díaz de Rada,&nbsp;C Beorlegui","doi":"10.23938/ASSN.1012","DOIUrl":"https://doi.org/10.23938/ASSN.1012","url":null,"abstract":"","PeriodicalId":7775,"journal":{"name":"Anales Del Sistema Sanitario De Navarra","volume":"45 2","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/c3/assn-45-02-e1012.PMC10130792.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9353553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Anales Del Sistema Sanitario De Navarra
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1